Fasenra Injection, Solution
Product Images NDC 0310-1745

Product Visual Gallery

This gallery contains 26 technical images submitted to the FDA as part of the official labeling for Fasenra (NDC 0310-1745). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fasenra_30mg_ml_single-dose_prefilled_syringe_carton (Fasenra 30 mg mL Carton)

FASENRA (benralizumab) Injection 30 mg/mL label for a single-dose prefilled syringe. The packaging indicates subcutaneous injection only and includes storage instructions to refrigerate at 36°F - 46°F (2°C - 8°C) in the original carton to protect from light. The labeler is AstraZeneca Pharmaceuticals LP.*

FDA Label Image

Fasenrapen-30mg_ml_single_dose_autoinjector_carton (Fasenrapen 30mg mL Single Dose Autoinjector Carton)

FASENRA Pen (benralizumab) Injection, 30 mg/mL, is a single-dose prefilled autoinjector for subcutaneous use. The label instructs storing the product refrigerated at 2°C to 8°C and warns against shaking, freezing, or heat exposure. The manufacturer is AstraZeneca Pharmaceuticals LP.*

FDA Label Image

Figure 2 (Figure 02)

A line graph showing the probability (%) of experiencing an exacerbation over 48 weeks for Benralizumab 30 mg administered every 8 weeks versus placebo. The graph includes two curves with error bars, indicating a lower probability of exacerbation for Benralizumab compared to placebo across the study period.*

FDA Label Image

Figure_3_change_from_baseline_fev1 (Figure 3 Change From Baseline Fev1)

A line graph comparing the change from baseline FEV1 (L) over 56 weeks between FASENRA (Benralizumab) 30 mg every 8 weeks and placebo in a high ICS dose group. The solid line represents FASENRA, showing higher improvement than the dashed placebo line. Sample sizes are indicated below the timeline.*

FDA Label Image

Figure 1 Prefilled Syringe Components (Image 01)

An instructional diagram of a prefilled syringe illustrating its components. Labeled parts include the plunger head, plunger, needle guard activation clips, finger flange, syringe body, label with expiration date, viewing window, needle, and needle cover.*

FDA Label Image

Step 2 Needle Cover Image (Image 02)

An instructional illustration showing a hand holding a syringe with a needle cap being removed by another hand. The arrow indicates the direction to pull off the cap, demonstrating preparation of an injection.*

FDA Label Image

Step 3 (Image 03)

A black and white instructional illustration depicting a hand holding a syringe to administer a subcutaneous injection into the forearm, demonstrating the injection technique for the drug FASENRA (benralizumab) injection, solution.*

FDA Label Image

Step 4 (Image 04)

An instructional illustration showing a hand administering a subcutaneous injection with a syringe into the fingertip, indicating the injection technique with a downward-pointing arrow.*

FDA Label Image

Step 5 (Image 05)

An instructional line drawing showing a hand holding a prefilled syringe, demonstrating the step of removing the cap by pulling it upward before injection.*

FDA Label Image

Step 10 Sharps Container

An instructional illustration showing a hand holding a prefilled syringe with a purple cap, positioned above a red sharps disposal container, demonstrating proper disposal of the syringe after use.*

FDA Label Image

Step 1 Gather Supplies

An instructional illustration showing five items for subcutaneous injection of FASENRA (Benralizumab). Items include a FASENRA pen injector, alcohol wipe packets, cotton balls or gauze, adhesive bandages, and a red sharps disposal container. The image visually represents the supplies commonly used for administering and safely disposing of the medication injection.*

FDA Label Image

Step 2 30 Minute Clock

An illustration of a stopwatch showing 30 minutes elapsed, with the right half filled in blue and the left half white. The number '30' and the word 'min' indicate a 30-minute time duration.*

FDA Label Image

Step 3 Fasenra Pen Viewing Window

An instructional illustration showing a hand holding a FASENRA (Benralizumab) injection pen, highlighting the device used for subcutaneous administration of the medication.*

FDA Label Image

Step 4 Choose The Injection Site

An anatomical illustration showing recommended subcutaneous injection sites for FASENRA (Benralizumab). Highlighted areas include the upper arms, abdomen (excluding a 2-inch area around the navel), and the front of the thighs. A label indicates the injection is intended for the caregiver site only.*

FDA Label Image

Step 5 Clean The Injection Site

An illustration showing a hand using a cloth or wipe to clean or disinfect a surface. The image likely represents part of the preparation process for administering an injection, emphasizing cleanliness before use.*

FDA Label Image

Step 6 Pull Off The Cap

Illustration showing hands removing the cap from a subcutaneous injection pen for FASENRA (benralizumab). The image depicts the proper step of detaching the pen cap prior to injection, with an arrow indicating the direction to pull the cap away from the pen.*

FDA Label Image

Step 7 A Position The Pen At The Injection Site

An instructional diagram showing hands holding a FASENRA prefilled syringe at a 90-degree angle to the skin, demonstrating the correct subcutaneous injection technique for administering the benralizumab injection solution.*

FDA Label Image

Step 7 B Position Press Down Firmly

Illustration showing a hand administering a subcutaneous injection using a pen injector device. The device is held vertically and positioned above the injection site on the forearm or hand, with the other hand stabilizing the skin.*

FDA Label Image

Step 7 C Hold Down Firmly For 15 Seconds

An instructional illustration showing a hand holding a FASENRA injection device for subcutaneous injection. A stopwatch icon with "1 sec" indicates to hold the device in place for one second during administration.*

FDA Label Image

Step 7 D Lift The Fasenra Pen Straight Up

An instructional illustration showing a hand holding a pen-like injection device above a forearm, with an upward arrow indicating the motion to remove the cap or prepare for subcutaneous injection. This likely demonstrates part of the administration process for FASENRA (Benralizumab) injection solution.*

FDA Label Image

Step 8 Check The Viewing Window

An instructional illustration showing a close-up view of a FASENRA prefilled injection pen, held by a hand. The focus is on the dose window of the device, which displays a colored indicator bar, likely to show the status of the injection. The pen has a teal cap and purple components, consistent with FASENRA subcutaneous injection branding.*

FDA Label Image

Step 8 Viewing Window After Injection

The image shows a single-use prefilled syringe of FASENRA (benralizumab) injection. The syringe appears to be a 30 mg/mL strength in a clear barrel with a visible plunger and needle cover. No additional labeling or packaging details are visible.*

FDA Label Image

Step 8 Viewing Window Before Injection

An illustration showing a close-up of a device or component, possibly an injection syringe or pen, with a visible indicator window. The image focuses on the dosage indicator or scale within the device, relevant for subcutaneous injection administration.*

FDA Label Image

Step 9 Check The Injection Site

An illustration showing a hand grasping a small, crumpled piece of cloth or tissue, positioned above a surface, likely demonstrating a step in a cleaning or preparation process related to injection administration.*

FDA Label Image

Your Fasenra Pen After Use

An illustration labeled 'After Use' showing a prefilled injection pen with a green plunger visible inside and a needle guard covering the needle end. The pen is designed for subcutaneous injection, corresponding to FASENRA injection use.*

FDA Label Image

Your Fasenra Pen Before Use

An instructional diagram showing a FASENRA prefilled syringe before use. Key parts labeled include the cap, viewing window to observe the liquid medicine, the liquid medicine itself, and the label displaying the expiration date on the syringe barrel. The syringe is designed for subcutaneous injection of Benralizumab.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.